newsfilter
← Latest News
PR Newswire·

Eisai's Commitment to Scientific Evidence and Patient Safety

Hope for Patients with Early Alzheimer's Disease TOKYO, Jan. 6, 2023 /PRNewswire/ -- LEQEMBI™ (lecanemab-rimb) has the potential to make a difference for people living with early Alzheimer's disease (AD),